PT-141
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II, FDA-approved for hypoactive sexual desire disorder and studied for its effects on sexual function.
Free Shipping
over $200
Secure Checkout
256-bit SSL
Description
What is PT-141?PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide that acts as an agonist of melanocortin receptors, primarily MC4R and MC3R, in the central nervous system. It was derived from research on Melanotan II and developed specifically for its effects on sexual function.
Unlike phosphodiesterase inhibitors that work on vascular mechanisms, PT-141 acts centrally through melanocortin pathways in the brain to modulate sexual desire and arousal. This unique mechanism of action represents a different approach to sexual dysfunction research.
PT-141 was approved by the FDA in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved medication that works through melanocortin receptor pathways for this indication.
Research Applications
Areas of InvestigationSexual Function Research
Melanocortin Receptor Pharmacology
Central Nervous System Signaling
Compound Profile
Technical specificationsMolecular Profile
Form
Storage & Stability
Storage (Pre-Reconstitution)
Regulatory & Research Status
COA's (Certificate of Analysis)
Third Party Tested by Freedom DiagnosticsFrequently Asked Questions
Common questions about PT-141 researchFast & SecureUS Shipping
Orders processed within 1 business day, with tracked delivery
Batch-LevelTraceability
Products tied to specific lot numbers and documentation
DedicatedResearch Support
Responsive assistance for documentation and order inquiriers
SecureCheckout
Encrypted transactions and protected customer data